会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Multicomponent vaccines
    • 多组分疫苗
    • US08017133B2
    • 2011-09-13
    • US12710790
    • 2010-02-23
    • Joseph M. PattiTimothy J. FosterMagnus Hook
    • Joseph M. PattiTimothy J. FosterMagnus Hook
    • A61K39/085
    • C07K16/1271A61K39/085
    • Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus and other bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes a fibrinogen binding domain of a fibrinogen binding protein and a bacterial component such as a capsular polysaccharide, and both active and passive vaccines based on these components are also provided, along with methods of treating infection using these compositions and vaccines.
    • 提供了有助于预防和治疗葡萄球菌感染的多组分疫苗,其包括某些所选择的细菌结合蛋白或其片段的组合,或对那些蛋白质或片段的抗体。 通过仔细选择蛋白质,片段或抗体,提供疫苗,其对广泛的葡萄球菌和其他细菌菌株和针对在对数生长曲线的不同阶段表达的蛋白质提供保护。 在本发明的一个实施方案中,提供了包括纤维蛋白原结合蛋白的纤维蛋白原结合结构域和诸如荚膜多糖的细菌组分的组合物,以及基于这些组分的主动和被动疫苗以及方法 使用这些组合物和疫苗治疗感染。
    • 9. 发明申请
    • Compositions for inhibiting thrombin-induced coagulation and methods of use
    • 用于抑制凝血酶诱导的凝血的组合物及其使用方法
    • US20060110380A1
    • 2006-05-25
    • US11010406
    • 2004-12-14
    • Stacey DavisMagnus Hook
    • Stacey DavisMagnus Hook
    • A61K38/48
    • C07K14/31A61K38/164A61K38/482A61K2300/00
    • A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a fibrinogen-binding protein capable of binding at the N-terminal Bβ chain of fibrinogen, such as SdrG or Fbe, or their respective binding regions such as the A domain. In addition, compositions comprising effective amounts of the fibrinogen-binding proteins are also provided. The present anti-coagulation compositions have been shown to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B and the resulting anti-coagulation effects can be achieved without potential for causing or exacerbating unwanted side effects such as thrombocytopenia associated with prior art anticoagulants such as heparin.
    • 一种实现安全有效的治疗或预防潜在有害的血块,或在需要时抑制血液凝固的方法,例如在包括中风,心肌梗死,镰状细胞危象和静脉血栓形成在内的各种疾病状况下,是一种方法 通过施用能够在纤维蛋白原的N-末端Bbeta链(例如SdrG或Fbe)或其各自的结合区域如A结构域结合的纤维蛋白原结合蛋白提供。 此外,还提供了包含有效量的纤维蛋白原结合蛋白的组合物。 已经显示本发明的抗凝组合物通过干扰纤维蛋白肽B的释放来抑制凝血酶诱导的纤维蛋白凝块形成,并且可以实现所得的抗凝血作用,而不会引起或加剧不期望的副作用,例如与先前相关的血小板减少症 艺术抗凝剂如肝素。